Chem-/Biotech

MSC-products for clinical trails and medicines

MDTB Cell Manufacturing GmbH

MDTB Cell Manufacturing GmbH is a life science company, specializing in the development and industrial production of innovative cell therapies. The company originated from years of research at the Technical University of Dresden and is led by an interdisciplinary team. MDTB develops and produces the pharmaceutical agent DESACELL®, which is based on mesenchymal stromal cells (UC-MSC) derived from donated umbilical cord tissue. The company focuses on the treatment of severe inflammation-associated diseases such as septic shock, acute graft-versus-host disease (GvHD), and bronchopulmonary dysplasia (BPD). MDTB’s patented platform technology enables GMP-compliant, cost-efficient, and scalable production of highly effective, storable cell therapy products.

The company’s goal is to create new therapeutic options for previously hard-to-treat and life-threatening diseases, close the care gap in the field of cell therapies, and thus make a sustainable contribution to improving patient care and relieving healthcare systems.

TGFS has held a stake in the company since 2024.